DAS THERAPEUTICS

The mission of DAS is to identify, acquire and develop unique assets for conditions overlooked or under-served by current treatment approaches to improve patient outcomes... Our first company, DAS-MG, has an innovative combination therapy (DAS-001) for treating the symptoms of Myasthenia Gravis... Myasthenia gravis is a debilitating, chronic autoimmune disease of the neuromuscular junction affecting a person's muscle strength and ability to function. Current treatment options may cause side effects that lead to significant tolerability issues. DAS-001 is a proposed fixed-dose combination tablet that combines the gold standard first-line treatment, pyridostigmine, with an antagonist of the gastrointestinal side effects of pyridostigmine.

Also known as: DAS Therapeutics, Inc.